High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant.

Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group. Hematol Rep (2012) 0.75

International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73

Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 11.27

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol (1998) 10.77

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia (2010) 3.31

Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood (2001) 2.82

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76

Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet (2000) 2.72

Condom use in multi-ethnic neighborhoods of San Francisco: the population-based AMEN (AIDS in Multi-Ethnic Neighborhoods) Study. Am J Public Health (1992) 2.71

Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut (2005) 2.62

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact (2000) 2.60

Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60

Detection of biofilm formation among the clinical isolates of Staphylococci: an evaluation of three different screening methods. Indian J Med Microbiol (2006) 2.43

First direct observation of a nearly ideal graphene band structure. Phys Rev Lett (2009) 2.41

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia (2007) 2.28

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia (2009) 2.28

Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet (1995) 2.26

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood (1997) 2.13

Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol (2001) 2.10

Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood (1995) 2.00

NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem (2000) 1.99

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98

An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Mol Cell Biol (2000) 1.97

Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood (1988) 1.95

Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood (1999) 1.89

A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene (2006) 1.89

VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol (1990) 1.87

Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant (2006) 1.85

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84

Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood (2001) 1.80

Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. JAMA (1990) 1.78

Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med (1990) 1.78

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol (1993) 1.76

Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma (2005) 1.75

Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70

Stent-assisted coiling versus balloon remodeling of wide-neck aneurysms: comparison of angiographic outcomes. AJNR Am J Neuroradiol (2013) 1.69

Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood (1998) 1.68

Morphometry of the human pulmonary arterial tree. Circ Res (1973) 1.65

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant (2007) 1.65

Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62

The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J (1999) 1.62

Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2. J Immunol (1985) 1.62

The impact of diuretic therapy on reported sexual function. Arch Intern Med (1991) 1.61

The 5q-anomaly. Cancer Genet Cytogenet (1985) 1.60

Vertebral artery dissection and pontine infarct after chiropractic manipulation. Am J Emerg Med (2001) 1.60

Graft-versus-myeloma effect: proof of principle. Blood (1996) 1.58

Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood (1998) 1.58

DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev (1993) 1.58